Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial

Maureen R. Horton, Victoria Santopietro, Leena Mathew, Karen M. Horton, Albert J. Polito, Mark C. Liu, Sonye K. Danoff, Noah Lechtzin

Research output: Contribution to journalArticle

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder of unknown cause with no effective treatment. Cough affects up to 80% of patients with IPF, is frequently disabling, and lacks effective therapy. Objective: To determine the efficacy of thalidomide in suppressing cough in patients with IPF. Design: 24-week, double-blind, 2-treatment, 2-period crossover trial. (ClinicalTrials.gov registration number: NCT00600028) Setting: 1 university center. Participants: 98 participants were screened, 24 were randomly assigned, 23 received treatment (78.3% men; mean age, 67.6 years; mean FVC, 70.4% predicted), and 20 completed both treatment periods. Measurements: The primary end point was cough-specific quality of life measured by the Cough Quality of Life Questionnaire (CQLQ). Secondary end points were visual analogue scale of cough and the St. George's Respiratory Questionnaire (SGRQ). For all measures, lower scores equaled improved cough or respiratory quality of life. Results: CQLQ scores significantly improved with thalidomide (mean difference vs. placebo, -11.4 [95% CI, -15.7 to -7.0]; P <0.001). Thalidomide also significantly improved scores on the visual analogue scale of cough (mean difference vs. placebo, -31.2 [CI, -45.2 to -17.2]; P <0.001). In participants receiving thalidomide, scores from the total SGRQ, SGRQ symptom domain, and SGRQ impact domain improved compared with those of participants receiving placebo. Adverse events were reported in 74% of patients receiving thalidomide and 22% receiving placebo; constipation, dizziness, and malaise were more frequent with thalidomide. Limitation: This was a single-center study of short duration and small sample size focused on symptom-specific quality of life. Conclusion: Thalidomide improved cough and respiratory quality of life in patients with IPF. A larger trial is warranted to assess these promising results.

Original languageEnglish (US)
Pages (from-to)398-406
Number of pages9
JournalAnnals of Internal Medicine
Volume157
Issue number6
StatePublished - Sep 18 2012

Fingerprint

Idiopathic Pulmonary Fibrosis
Thalidomide
Cough
Quality of Life
Placebos
Therapeutics
Visual Analog Scale
Dizziness
Constipation
Sample Size
Cross-Over Studies
Surveys and Questionnaires

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis : A randomized trial. / Horton, Maureen R.; Santopietro, Victoria; Mathew, Leena; Horton, Karen M.; Polito, Albert J.; Liu, Mark C.; Danoff, Sonye K.; Lechtzin, Noah.

In: Annals of Internal Medicine, Vol. 157, No. 6, 18.09.2012, p. 398-406.

Research output: Contribution to journalArticle

@article{4dfdec42aede4e888fd26617192bdd45,
title = "Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial",
abstract = "Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder of unknown cause with no effective treatment. Cough affects up to 80{\%} of patients with IPF, is frequently disabling, and lacks effective therapy. Objective: To determine the efficacy of thalidomide in suppressing cough in patients with IPF. Design: 24-week, double-blind, 2-treatment, 2-period crossover trial. (ClinicalTrials.gov registration number: NCT00600028) Setting: 1 university center. Participants: 98 participants were screened, 24 were randomly assigned, 23 received treatment (78.3{\%} men; mean age, 67.6 years; mean FVC, 70.4{\%} predicted), and 20 completed both treatment periods. Measurements: The primary end point was cough-specific quality of life measured by the Cough Quality of Life Questionnaire (CQLQ). Secondary end points were visual analogue scale of cough and the St. George's Respiratory Questionnaire (SGRQ). For all measures, lower scores equaled improved cough or respiratory quality of life. Results: CQLQ scores significantly improved with thalidomide (mean difference vs. placebo, -11.4 [95{\%} CI, -15.7 to -7.0]; P <0.001). Thalidomide also significantly improved scores on the visual analogue scale of cough (mean difference vs. placebo, -31.2 [CI, -45.2 to -17.2]; P <0.001). In participants receiving thalidomide, scores from the total SGRQ, SGRQ symptom domain, and SGRQ impact domain improved compared with those of participants receiving placebo. Adverse events were reported in 74{\%} of patients receiving thalidomide and 22{\%} receiving placebo; constipation, dizziness, and malaise were more frequent with thalidomide. Limitation: This was a single-center study of short duration and small sample size focused on symptom-specific quality of life. Conclusion: Thalidomide improved cough and respiratory quality of life in patients with IPF. A larger trial is warranted to assess these promising results.",
author = "Horton, {Maureen R.} and Victoria Santopietro and Leena Mathew and Horton, {Karen M.} and Polito, {Albert J.} and Liu, {Mark C.} and Danoff, {Sonye K.} and Noah Lechtzin",
year = "2012",
month = "9",
day = "18",
language = "English (US)",
volume = "157",
pages = "398--406",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis

T2 - A randomized trial

AU - Horton, Maureen R.

AU - Santopietro, Victoria

AU - Mathew, Leena

AU - Horton, Karen M.

AU - Polito, Albert J.

AU - Liu, Mark C.

AU - Danoff, Sonye K.

AU - Lechtzin, Noah

PY - 2012/9/18

Y1 - 2012/9/18

N2 - Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder of unknown cause with no effective treatment. Cough affects up to 80% of patients with IPF, is frequently disabling, and lacks effective therapy. Objective: To determine the efficacy of thalidomide in suppressing cough in patients with IPF. Design: 24-week, double-blind, 2-treatment, 2-period crossover trial. (ClinicalTrials.gov registration number: NCT00600028) Setting: 1 university center. Participants: 98 participants were screened, 24 were randomly assigned, 23 received treatment (78.3% men; mean age, 67.6 years; mean FVC, 70.4% predicted), and 20 completed both treatment periods. Measurements: The primary end point was cough-specific quality of life measured by the Cough Quality of Life Questionnaire (CQLQ). Secondary end points were visual analogue scale of cough and the St. George's Respiratory Questionnaire (SGRQ). For all measures, lower scores equaled improved cough or respiratory quality of life. Results: CQLQ scores significantly improved with thalidomide (mean difference vs. placebo, -11.4 [95% CI, -15.7 to -7.0]; P <0.001). Thalidomide also significantly improved scores on the visual analogue scale of cough (mean difference vs. placebo, -31.2 [CI, -45.2 to -17.2]; P <0.001). In participants receiving thalidomide, scores from the total SGRQ, SGRQ symptom domain, and SGRQ impact domain improved compared with those of participants receiving placebo. Adverse events were reported in 74% of patients receiving thalidomide and 22% receiving placebo; constipation, dizziness, and malaise were more frequent with thalidomide. Limitation: This was a single-center study of short duration and small sample size focused on symptom-specific quality of life. Conclusion: Thalidomide improved cough and respiratory quality of life in patients with IPF. A larger trial is warranted to assess these promising results.

AB - Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder of unknown cause with no effective treatment. Cough affects up to 80% of patients with IPF, is frequently disabling, and lacks effective therapy. Objective: To determine the efficacy of thalidomide in suppressing cough in patients with IPF. Design: 24-week, double-blind, 2-treatment, 2-period crossover trial. (ClinicalTrials.gov registration number: NCT00600028) Setting: 1 university center. Participants: 98 participants were screened, 24 were randomly assigned, 23 received treatment (78.3% men; mean age, 67.6 years; mean FVC, 70.4% predicted), and 20 completed both treatment periods. Measurements: The primary end point was cough-specific quality of life measured by the Cough Quality of Life Questionnaire (CQLQ). Secondary end points were visual analogue scale of cough and the St. George's Respiratory Questionnaire (SGRQ). For all measures, lower scores equaled improved cough or respiratory quality of life. Results: CQLQ scores significantly improved with thalidomide (mean difference vs. placebo, -11.4 [95% CI, -15.7 to -7.0]; P <0.001). Thalidomide also significantly improved scores on the visual analogue scale of cough (mean difference vs. placebo, -31.2 [CI, -45.2 to -17.2]; P <0.001). In participants receiving thalidomide, scores from the total SGRQ, SGRQ symptom domain, and SGRQ impact domain improved compared with those of participants receiving placebo. Adverse events were reported in 74% of patients receiving thalidomide and 22% receiving placebo; constipation, dizziness, and malaise were more frequent with thalidomide. Limitation: This was a single-center study of short duration and small sample size focused on symptom-specific quality of life. Conclusion: Thalidomide improved cough and respiratory quality of life in patients with IPF. A larger trial is warranted to assess these promising results.

UR - http://www.scopus.com/inward/record.url?scp=84868327008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868327008&partnerID=8YFLogxK

M3 - Article

C2 - 22986377

AN - SCOPUS:84868327008

VL - 157

SP - 398

EP - 406

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -